Gene · 11280
SCN11A: sodium voltage-gated channel alpha subunit 11
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SCN11A: sodium voltage-gated channel alpha subunit 11. Genes, record 11280. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/11280
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9UI33 | Sodium channel protein type 11 subunit alpha | 1,791 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents48
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 63930 | Q9UI33 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 63932 | Q9UI33 | Espacenet |
| US 12516308 B2 | 2026-01-06 | 2437 | Q9UI33 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 4058 | Q9UI33 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 3839 | Q9UI33 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 3839 | Q9UI33 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 4058 | Q9UI33 | Espacenet |
| JP 2024520478 A | 2024-05-24 | 36 | Q9UI33 | Espacenet |
| US 11898179 B2 | 2024-02-13 | 2437 | Q9UI33 | Espacenet |
| US 11464217 B2 | 2022-10-11 | 29 | Q9UI33 | Espacenet |
1 to 10 of 48
See all 48 patentsDrugs84
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AFACIFENACIN | CHEMBL3545165 | Sodium channel protein type XI alpha subunit blocker | BLOCKER | ChEMBL |
| ARTICAINE | CHEMBL1093 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
| ARTICAINE HYDROCHLORIDE | CHEMBL1200819 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
| BENOXINATE | CHEMBL1200 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
| BENOXINATE HYDROCHLORIDE | CHEMBL1200654 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
| CARBAMAZEPINE | CHEMBL108 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
| CENOBAMATE | CHEMBL3989949 | Sodium channel alpha subunit inhibitor | INHIBITOR | ChEMBL |
| CHLOROPROCAINE | CHEMBL1179047 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
| CHLOROPROCAINE HYDROCHLORIDE | CHEMBL944 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
| COCAINE | CHEMBL370805 | Sodium channel alpha subunit blocker | BLOCKER | ChEMBL |
1 to 10 of 84
See all 84 drugsTrials1,301
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07599800 | LIDOCAINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07592143 | LIDOCAINE | PHASE3 | ClinicalTrials.gov | |
| NCT07588750 | TOPIRAMATE | ClinicalTrials.gov | ||
| NCT07572994 | LIDOCAINE | ClinicalTrials.gov | ||
| NCT07568496 | LIDOCAINE | ClinicalTrials.gov | ||
| NCT07547371 | ARTICAINE HYDROCHLORIDE | ClinicalTrials.gov | ||
| NCT07546370 | PRILOCAINE | PHASE4 | ClinicalTrials.gov | |
| NCT07546370 | LIDOCAINE | PHASE4 | ClinicalTrials.gov | |
| NCT07536594 | LIDOCAINE | ClinicalTrials.gov | ||
| NCT07511400 | LIDOCAINE | EARLY_PHASE1 | ClinicalTrials.gov |
1 to 10 of 1,301
See all 1,301 trialsNIH grants928
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SCN11A papers | Newest fiscal year |
|---|---|---|---|
| UL1TR001863 | Yale Clinical and Translational Science Award | 11 | 2025 |
| I50RX002999 | Center for Restoration of Nervous System Function | 5 | 2025 |
| R01NS034509 | Functional Genetics of the Neuronal Sodium Channel Gene SCN8A | 4 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| R01AR060364 | Molecular Pathways of Pain Generation in Osteoarthritis | 3 | 2025 |
| R01AR064251 | Osteoarthritis Progression And Sensory Pathway Alterations | 3 | 2025 |
| R01HL086694 | From GWAS loci to blood pressure genes, variants & mechanisms - Renewal | 3 | 2025 |
| T32GM136651 | Medical Scientist Training Program | 3 | 2025 |
| T32NS045549 | Interdisciplinary Training Program in Pain Research | 3 | 2025 |
| U19NS130608 | Human Nociceptor and Spinal Cord Molecular Signature Center | 3 | 2025 |
1 to 10 of 928Source NIH's project files
See all 928 nih grantsPapers1,589
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Chasing the Wrong Door for 30 Years: Is Suzetrigine the Key to Selective Pain Relief? | Medicina (Kaunas) | 2026 | 42796305 | PubTator, text mining | PubMed |
| Cu Doping Activates SnS2 Basal Planes for Efficient CO2 Electroreduction to Formate. | Langmuir | 2026 | 42714836 | PubTator, text mining | PubMed |
| A designer saxitoxin-engineered sodium channel pair as a general tool for subtype-selective inhibition. | Cell Chem Biol | 2026 | 42679814 | PubTator, text mining | PubMed |
| Nonaddictive Analgesia: New Approaches That Target the Hodgkin-Huxley NaV/KV Dyad. | Annu Rev Pharmacol Toxicol | 2026 | 42594287 | PubTator, text mining | PubMed |
| New insight into RNA biomarkers in neuropathic pain: a clinician-neuroscientist roadmap to translational testing and treatment monitoring a clinical review. | Front Pain Res (Lausanne) | 2026 | 42534835 | PubTator, text mining | PubMed |
| Magnetoelastic Transport-Path Reconstruction and Giant Magnetotransport Responses in a Two-Dimensional Antiferromagnet. | Nano Lett | 2026 | 42503889 | PubTator, text mining | PubMed |
| Phase-Restructured SnS2 Nanodots: Unlocking ORR Activity through Thermal Stress-Mediated Fracturing. | Small | 2026 | 42434923 | PubTator, text mining | PubMed |
| Gate-Tunable Magnetoresistance in Antiferromagnetic van der Waals FePS3 Transistors. | Nano Lett | 2026 | 42407046 | PubTator, text mining | PubMed |
| Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda. | CNS Drugs | 2026 | 42334794 | PubTator, text mining | PubMed |
| Selectivity Reversal from CO to Ethylene Products in CO2 Photoreduction via Electronic Modulation of SnS2 Using a Vinyl-Bridged Porous Organic Polymer. | J Am Chem Soc | 2026 | 42330158 | PubTator, text mining | PubMed |
1 to 10 of 1,589
See all 1,589 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/11280
GET https://conductscience.org/api/genes/v1/11280/patents?page=2